Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 5:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: High IOP Clear all
Completed Not applicable Interventional

Study to Determine if Taking OTC Non-Steroidal Anti-Inflammatory Affects Eye Pressure in Patients Using Glaucoma Drops

NCT00402493
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
ibuprofen, latanoprost, brimonidine, Ibuprofen, brimonidine, latanoprost, Ibuprofen
Drug
Lead sponsor
Philadelphia Eye Associates
Other
Eligibility
21 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Willingboro, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 9, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

NCT05451329
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Sep 9, 2026, 5:53 AM EDT
Completed No phase listed Observational

Collection of Blood Specimens From Patients in AL-3789 Studies for Elevated Intraocular Pressure (IOP)

NCT00691639
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
Blood Collection Only
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2009 · Synced Sep 9, 2026, 5:53 AM EDT
Completed No phase listed Observational Results available

The Cutting Efficiency of Hybrid Tips in Different Grades of Cataract

NCT05495555
View directory record Official record
Conditions
Cataract
Interventions
INTREPID® Hybrid tip
Device
Lead sponsor
Cataract and Laser Institute of Southern Oregon
Other
Eligibility
50 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 9, 2026, 5:53 AM EDT
Not listed Phase 3 Interventional

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

NCT05165290
View directory record Official record
Conditions
Elevated Intraocular Pressure
Interventions
Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%
Drug
Lead sponsor
TearClear Corp
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Garden Grove, California • Glendale, California • Mission Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Sep 9, 2026, 5:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Phacoemulsification at High IOP and Physiologic IOP: Impact on Anterior and Posterior Segment Physiology

NCT05765201
View directory record Official record
Conditions
Nuclear Cataract
Interventions
High IOP, Low IOP
Other
Lead sponsor
Matthew Rauen
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
West Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 7, 2024 · Synced Sep 9, 2026, 5:53 AM EDT
Not yet recruiting Not applicable Interventional

The Impact of Physiologic Cataract Surgery on Patient Comfort and Medication Usage

NCT07223866
View directory record Official record
Conditions
Cataract and IOL Surgery, Cataract Surgery Anesthesia, Cataract Surgery Experience, Nuclear Cataract
Interventions
High IOP Setting, Low IOP Setting
Device
Lead sponsor
Matthew Rauen
Other
Eligibility
60 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 9, 2026, 5:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Intraocular Pressure Measurements Between Reichert Tono-Vera Tonometer and Goldmann Tonometry

NCT04360369
View directory record Official record
Conditions
Intraocular Pressure, Glaucoma
Interventions
IOP with Goldmann Applanation Tonometer, IOP with comparator ORA G3 and ic100 tonometers, IOP with Tono-Vera Tonometer
Device
Lead sponsor
Reichert, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 2, 2022 · Synced Sep 9, 2026, 5:53 AM EDT
Completed Phase 2 Interventional

Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure

NCT01060579
View directory record Official record
Conditions
Glaucoma
Interventions
AR-12286 0.5% ophthalmic solution, AR-12286 0.25% Ophthalmic solution, Latanoprost ophthalmic solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
18
States / cities
Inglewood, California • Petaluma, California • Poway, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Sep 9, 2026, 5:53 AM EDT
Completed Not applicable Interventional Results available

180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma

NCT02628223
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension, Glaucoma, Open Angle, Pseudo-exfoliative, Pigment Dispersion Syndrome, Glaucoma
Interventions
Selective Laser Trabeculoplasty, Neodymium:Yttrium Aluminum Garnet (YAG) laser
Procedure · Device
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Wilmington, Delaware • Thorndale, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Sep 9, 2026, 5:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Less Discomfort and Less Pharmacology. Cataract Surgery at Physiologic Intraocular Pressure (IOP)

NCT06325397
View directory record Official record
Conditions
Nuclear Cataract
Interventions
High Intraocular Pressure (IOP), Low Intraocular Pressure (IOP)
Other
Lead sponsor
Matthew Rauen
Other
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
West Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 9, 2026, 5:53 AM EDT
Not yet recruiting Phase 4 Interventional

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

NCT07048886
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane
Drug
Lead sponsor
Center for Sight Las Vegas
Other
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 9, 2026, 5:53 AM EDT
Completed Phase 2 Interventional

A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)

NCT00902200
View directory record Official record
Conditions
Elevated Intraocular Pressure
Interventions
AR-12286, AR-12286 vehicle
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
8
States / cities
Pasadena, California • Petaluma, California • Brooksville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 9, 2026, 5:53 AM EDT
Not yet recruiting Phase 2 Interventional

Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)

NCT07808333
View directory record Official record
Conditions
Glaucoma, Open-angle, Primary Open Angle Glaucoma (POAG)
Interventions
Nicotinamide, Standard Glaucoma Therapy
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 80 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 9, 2026, 5:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk

NCT01442896
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Sep 9, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

NCT03233308
View directory record Official record
Conditions
Primary Open Angle Glaucoma or Ocular Hypertension
Interventions
Netarsudil Ophthalmic Solution 0.02%, Placebo Comparator
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 9, 2026, 5:53 AM EDT
Completed Not applicable Interventional

iCare HOME2 Clinical Trial

NCT05162989
View directory record Official record
Conditions
Intraocular Pressure, Glaucoma
Interventions
iCare HOME2 vs iCare IC200
Device
Lead sponsor
Icare Finland Oy
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2021 · Synced Sep 9, 2026, 5:53 AM EDT
Completed Phase 2 Interventional

Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).

NCT04830397
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
QLS-101, Timolol Maleate
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Albany, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 9, 2026, 5:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

How Accurately Does the Diopsys Visual Evoked Potential (VEP) Vision Testing System Detect Glaucoma?

NCT02622178
View directory record Official record
Conditions
Glaucoma Diagnosis
Interventions
Optical Coherence Tomography, Visual evoked potential
Diagnostic Test
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Sep 9, 2026, 5:53 AM EDT
Completed No phase listed Observational Results available

Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

NCT00716742
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
1,099 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Murfreesboro, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Sep 9, 2026, 5:53 AM EDT
Terminated Phase 2 Interventional

A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

NCT00788541
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Anecortave Acetate Sterile Suspension, 6 mg/mL, Anecortave Acetate Sterile Suspension, 3.75 mg/mL, Anecortave Acetate Sterile Suspension, 96 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/ML, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Sep 9, 2026, 5:53 AM EDT
Completed Phase 2 Interventional

AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure

NCT01474135
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
0.25% AR-12286 / 0.004% travoprost, 0.5% AR-12286, 0.004% travoprost, 0.004% Travoprost
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Inglewood, California • Newport Beach, California • Petaluma, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 9, 2026, 5:53 AM EDT
Completed No phase listed Observational

2311 TURGOR Study -Surgical Efficiency and Postoperative Corneal Clarity With Near Physiologic vs High IOP Settings

NCT07144644
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Adjusting intraocular pressure (IOP) settings
Device
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Timeline
2024 – 2025
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 9, 2026, 5:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

TRK-3 Conformance to Standards for Tonometers

NCT06247072
View directory record Official record
Conditions
Glaucoma
Interventions
Tonometer
Device
Lead sponsor
Topcon Corporation
Industry
Eligibility
22 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
La Mesa, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Sep 9, 2026, 5:53 AM EDT